Adverse events associated with sequential immune checkpoint inhibitor and alectinib in patients with ALK-rearranged advanced non-small-cell lung cancer.

ABSTRACT:

Background

ALK tyrosine kinase inhibitors (TKIs) are the standard first-line therapy for ALK-rearranged [ALK fusion-positive (ALK+)] advanced non-small-cell lung cancer (NSCLC). In real-world practice, patients may receive immune checkpoint inhibitors (ICIs) before initiating ALK TKIs. We aimed to assess the frequency of treatment-related adverse events (TRAEs) associated with this sequential approach.

Patients and methods

We retrospectively analyzed alectinib-associated TRAEs in patients with advanced ALK+ NSCLC who received alectinib as their first TKI, with or without prior ICI exposure.

Results

We identified 166 patients, of whom 12 had prior ICI exposure. From alectinib initiation, the 12-month cumulative incidence in patients with versus without prior ICI was as

SUBMITTER: Cheung JM 

PROVIDER: S-EPMC12538423 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature